Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, today announced the launch of research grade ...

As often happens in science, the discovery of VIPR started with an observation that didn’t make sense.

CRISPR-Cas provides RNA-mediated adaptive immunity, but how its first RNA-guided effector arose is unclear. In this study, we report the discovery of Viral Interference Programmable Repeat (VIPR) ...

A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. CRISPR-mediated gene editing technology has ...

Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that causes Down syndrome (DS). Down syndrome is a genetic condition caused by an ...

“On second review, the PTAB was again ‘not persuaded that CVC has met its burden as junior party of showing that its inventors conceived of an embodiment of Count 1 before the Broad inventors had ...

In a decision announced today (March 26), the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (USPTO and PTAB, respectively) reaffirmed its original decision that the Broad Institute, ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act like molecular anchors. The work confirms these tags actively silence genes, ...

FDA rewrote drug safety rules so that human cell tests and computer models can support first human trials. What it means for trial volunteers and patients. An Indiana appeals court revived a ...

In 1959, French geneticist Jérôme Lejeune made a landmark discovery – Down syndrome was caused by the presence of an extra copy of chromosome 21. For over six decades since this revelation, our ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...